Whitehawk Therapeutics
WHWK
60 hedge funds and large institutions have $30.9M invested in Whitehawk Therapeutics in 2024 Q1 according to their latest regulatory filings, with 9 funds opening new positions, 17 increasing their positions, 17 reducing their positions, and 13 closing their positions.
550% more call options, than puts
Call options by funds: $13K | Put options by funds: $2K
15% more capital invested
Capital invested by funds: $26.8M → $30.9M (+$4.07M)
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
0% more repeat investments, than reductions
Existing positions increased: 17 | Existing positions reduced: 17
0.36% less ownership
Funds ownership: 54.16% → 53.81% (-0.36%)
8% less funds holding
Funds holding: 65 → 60 (-5)
31% less first-time investments, than exits
New positions opened: 9 | Existing positions closed: 13
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AI
Acuitas Investments
Seattle,
Washington
|
+$613K |
| 2 |
PA
Parallel Advisors
San Francisco,
California
|
+$298K |
| 3 |
SO
STRS Ohio
Columbus,
Ohio
|
+$287K |
| 4 |
Renaissance Technologies
New York
|
+$279K |
| 5 |
Citadel Advisors
Miami,
Florida
|
+$212K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Morgan Stanley
New York
|
-$1.07M |
| 2 |
BBA
Baker Bros. Advisors
New York
|
-$508K |
| 3 |
Ameriprise
Minneapolis,
Minnesota
|
-$209K |
| 4 |
LPC
Lion Point Capital
New York
|
-$166K |
| 5 |
Squarepoint
New York
|
-$93.3K |
WHWK Hedge Fund Activity: Q1 2024 in Review
60 of the 6,942 institutional investors tracked by Wall St. Rank reported a position in Whitehawk Therapeutics (WHWK) for Q1 2024, worth a combined $30.9M — up 15% from $26.8M a quarter earlier.
Sellers outnumbered buyers: 13 funds closed out of WHWK and 9 opened new positions — a net loss of 4 holders — while 17 trimmed existing stakes and 17 added.
The largest buyer was Acuitas Investments, opening a new position worth an estimated $613K. The largest seller was Morgan Stanley, cutting an estimated $1.07M.
- 60 institutional investors held Whitehawk Therapeutics (WHWK) as of Q1 2024, down from 65 in Q4 2023.
- Funds reported $30.9M of Whitehawk Therapeutics stock for Q1 2024, up 15% quarter-over-quarter.
- 9 funds opened new Whitehawk Therapeutics positions in Q1 2024 and 13 closed out, a net change of -4 holders.
- The largest Whitehawk Therapeutics buyer in Q1 2024 was Acuitas Investments, an estimated $613K added.
- The largest Whitehawk Therapeutics seller in Q1 2024 was Morgan Stanley, an estimated $1.07M sold.
Based on aggregated 13F filings for Q1 2024.